The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.28 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2026, as iBio, Inc. reports it. History and quarterly detail are in the app.
- Collaborative Revenues$100K
Leadership changes
From iBio, Inc.'s own filings, the day they're filed.
- Molly Carr · Chief Medical Officer · appointmenteff. 2026-07-31
- Elizabeth Stoner · director · appointmenteff. 2026-05-07
- K. Other · appointmenteff. 2026-05-07
Latest filings
- 8-K · Company announcement2026-08-28
- 10-K · Annual report2026-08-28
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-07-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about iBio, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when iBio, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.